Coherentmarketinsightsus

  Overactive bladder (OAB) is not a disease, it is a problem with bladder function that causes the sudden need to urinate. Diabetes, an enlarged prostate, and ageing are the major risk factors. Treatments such as pelvic floor muscle exercises, medication, and nerve stimulation can reduce or eliminate symptoms. Thus, with the increasing incidence of overactive bladder, worldwide, the demand for Overactive Bladder Treatment is also increasing. In October 2020, Zydus Cadila received final approval from the United States Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, for the treatment of overactive bladder. The company received approval to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg. This in turn is expected to accelerate the growth of the Overactive Bladder Treatment market. Frequent urination and urine leakage are the main symptoms of overactive bladder. Frequent urination is common in such patients. Overactiv...

  Overactive bladder (OAB) is classified as a syndrome rather than disease which comprises of a mix of various symptoms such as for example frequent urination, urgency to urinate, urine leakage and the requirement to urinate at least twice every night. There are several causes which can result in overactive bladder such as for example weak pelvic muscles, nerve damage as a result of trauma or diseases, Urinary Tract Infection (UTI), obesity, hormonal imbalance post menopause, medications, caffeine and alcohol. Parkinson's disease, Multiple sclerosis and stroke are several diseases that lead to an overactive bladder. Overactive Bladder Therapeutics contains treatments such as for example pelvic floor muscle exercises, medication and nerve stimulation can reduce or eliminate symptoms.Medications that relax the bladder may be great for relieving symptoms of overactive bladder and reducing episodes of urge incontinence. These drugs include: Tolterodine (Detrol) Oxybut...